|
13 Jan 2020 |
CNS Pharmaceuticals Licenses Breakthrough Technology from MD Anderson, Doubling its Drug Pipeline
|
|
13 Jan 2020 |
MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
|
|
13 Jan 2020 |
Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)
|
|
13 Jan 2020 |
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
|
|
13 Jan 2020 |
Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates
|
|
13 Jan 2020 |
Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog
|
|
13 Jan 2020 |
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
|
|
13 Jan 2020 |
Bayer and Daré Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®
|
|
13 Jan 2020 |
Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.
|
|
13 Jan 2020 |
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
|
|
13 Jan 2020 |
Update on Phase III STRENGTH trial for Epanova in mixed dyslipidaemia
|
|
13 Jan 2020 |
LYNPARZA® (olaparib) regulatory submission granted priority review in US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
|
|
13 Jan 2020 |
MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab (news with additional features)
|
|
13 Jan 2020 |
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
|
|
12 Jan 2020 |
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
|
|
12 Jan 2020 |
Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement
|
|
12 Jan 2020 |
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
|
|
12 Jan 2020 |
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
|
|
12 Jan 2020 |
Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study
|
|
12 Jan 2020 |
Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients
|
